196 related articles for article (PubMed ID: 23786330)
1. Comparison of insulators and promoters for expression of the Wiskott-Aldrich syndrome protein using lentiviral vectors.
Koldej RM; Carney G; Wielgosz MM; Zhou S; Zhan J; Sorrentino BP; Nienhuis AW
Hum Gene Ther Clin Dev; 2013 Jun; 24(2):77-85. PubMed ID: 23786330
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of gene therapy for Wiskott-Aldrich syndrome using a WAS promoter/cDNA-containing lentiviral vector and nonlethal irradiation.
Dupré L; Marangoni F; Scaramuzza S; Trifari S; Hernández RJ; Aiuti A; Naldini L; Roncarolo MG
Hum Gene Ther; 2006 Mar; 17(3):303-13. PubMed ID: 16544979
[TBL] [Abstract][Full Text] [Related]
3. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study.
Ferrua F; Cicalese MP; Galimberti S; Giannelli S; Dionisio F; Barzaghi F; Migliavacca M; Bernardo ME; Calbi V; Assanelli AA; Facchini M; Fossati C; Albertazzi E; Scaramuzza S; Brigida I; Scala S; Basso-Ricci L; Pajno R; Casiraghi M; Canarutto D; Salerio FA; Albert MH; Bartoli A; Wolf HM; Fiori R; Silvani P; Gattillo S; Villa A; Biasco L; Dott C; Culme-Seymour EJ; van Rossem K; Atkinson G; Valsecchi MG; Roncarolo MG; Ciceri F; Naldini L; Aiuti A
Lancet Haematol; 2019 May; 6(5):e239-e253. PubMed ID: 30981783
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic-specific lentiviral vectors circumvent cellular toxicity due to ectopic expression of Wiskott-Aldrich syndrome protein.
Toscano MG; Frecha C; Benabdellah K; Cobo M; Blundell M; Thrasher AJ; García-Olivares E; Molina IJ; Martin F
Hum Gene Ther; 2008 Feb; 19(2):179-97. PubMed ID: 18240968
[TBL] [Abstract][Full Text] [Related]
5. Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients.
Charrier S; Dupré L; Scaramuzza S; Jeanson-Leh L; Blundell MP; Danos O; Cattaneo F; Aiuti A; Eckenberg R; Thrasher AJ; Roncarolo MG; Galy A
Gene Ther; 2007 Mar; 14(5):415-28. PubMed ID: 17051251
[TBL] [Abstract][Full Text] [Related]
6. Improved lentiviral vectors for Wiskott-Aldrich syndrome gene therapy mimic endogenous expression profiles throughout haematopoiesis.
Frecha C; Toscano MG; Costa C; Saez-Lara MJ; Cosset FL; Verhoeyen E; Martin F
Gene Ther; 2008 Jun; 15(12):930-41. PubMed ID: 18323794
[TBL] [Abstract][Full Text] [Related]
7. Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome.
Astrakhan A; Sather BD; Ryu BY; Khim S; Singh S; Humblet-Baron S; Ochs HD; Miao CH; Rawlings DJ
Blood; 2012 May; 119(19):4395-407. PubMed ID: 22431569
[TBL] [Abstract][Full Text] [Related]
8. Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction.
Dupré L; Trifari S; Follenzi A; Marangoni F; Lain de Lera T; Bernad A; Martino S; Tsuchiya S; Bordignon C; Naldini L; Aiuti A; Roncarolo MG
Mol Ther; 2004 Nov; 10(5):903-15. PubMed ID: 15509508
[TBL] [Abstract][Full Text] [Related]
9. B-cell reconstitution after lentiviral vector-mediated gene therapy in patients with Wiskott-Aldrich syndrome.
Castiello MC; Scaramuzza S; Pala F; Ferrua F; Uva P; Brigida I; Sereni L; van der Burg M; Ottaviano G; Albert MH; Grazia Roncarolo M; Naldini L; Aiuti A; Villa A; Bosticardo M
J Allergy Clin Immunol; 2015 Sep; 136(3):692-702.e2. PubMed ID: 25792466
[TBL] [Abstract][Full Text] [Related]
10. Foamy virus vector-mediated gene correction of a mouse model of Wiskott-Aldrich syndrome.
Uchiyama T; Adriani M; Jagadeesh GJ; Paine A; Candotti F
Mol Ther; 2012 Jun; 20(6):1270-9. PubMed ID: 22215016
[TBL] [Abstract][Full Text] [Related]
11. Lentiviral-mediated gene therapy leads to improvement of B-cell functionality in a murine model of Wiskott-Aldrich syndrome.
Bosticardo M; Draghici E; Schena F; Sauer AV; Fontana E; Castiello MC; Catucci M; Locci M; Naldini L; Aiuti A; Roncarolo MG; Poliani PL; Traggiai E; Villa A
J Allergy Clin Immunol; 2011 Jun; 127(6):1376-84.e5. PubMed ID: 21531013
[TBL] [Abstract][Full Text] [Related]
12. Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy.
Avedillo Díez I; Zychlinski D; Coci EG; Galla M; Modlich U; Dewey RA; Schwarzer A; Maetzig T; Mpofu N; Jaeckel E; Boztug K; Baum C; Klein C; Schambach A
Mol Pharm; 2011 Oct; 8(5):1525-37. PubMed ID: 21851067
[TBL] [Abstract][Full Text] [Related]
13. A lentiviral vector encoding the human Wiskott-Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice.
Charrier S; Stockholm D; Seye K; Opolon P; Taveau M; Gross DA; Bucher-Laurent S; Delenda C; Vainchenker W; Danos O; Galy A
Gene Ther; 2005 Apr; 12(7):597-606. PubMed ID: 15616597
[TBL] [Abstract][Full Text] [Related]
14. Efficient transcriptional targeting of human hematopoietic stem cells and blood cell lineages by lentiviral vectors containing the regulatory element of the Wiskott-Aldrich syndrome gene.
Leuci V; Gammaitoni L; Capellero S; Sangiolo D; Mesuraca M; Bond HM; Migliardi G; Cammarata C; Aglietta M; Morrone G; Piacibello W
Stem Cells; 2009 Nov; 27(11):2815-23. PubMed ID: 19785032
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy for Wiskott-Aldrich syndrome: rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice.
Klein C; Nguyen D; Liu CH; Mizoguchi A; Bhan AK; Miki H; Takenawa T; Rosen FS; Alt FW; Mulligan RC; Snapper SB
Blood; 2003 Mar; 101(6):2159-66. PubMed ID: 12433691
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell functional improvement in a preclinical model of lentiviral-mediated gene therapy for Wiskott-Aldrich syndrome.
Catucci M; Prete F; Bosticardo M; Castiello MC; Draghici E; Locci M; Roncarolo MG; Aiuti A; Benvenuti F; Villa A
Gene Ther; 2012 Dec; 19(12):1150-8. PubMed ID: 22189416
[TBL] [Abstract][Full Text] [Related]
17. Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models.
Marangoni F; Bosticardo M; Charrier S; Draghici E; Locci M; Scaramuzza S; Panaroni C; Ponzoni M; Sanvito F; Doglioni C; Liabeuf M; Gjata B; Montus M; Siminovitch K; Aiuti A; Naldini L; Dupré L; Roncarolo MG; Galy A; Villa A
Mol Ther; 2009 Jun; 17(6):1073-82. PubMed ID: 19259069
[TBL] [Abstract][Full Text] [Related]
18. Development of lentiviral gene therapy for Wiskott Aldrich syndrome.
Galy A; Roncarolo MG; Thrasher AJ
Expert Opin Biol Ther; 2008 Feb; 8(2):181-90. PubMed ID: 18194074
[TBL] [Abstract][Full Text] [Related]
19. Defects in T-cell-mediated immunity to influenza virus in murine Wiskott-Aldrich syndrome are corrected by oncoretroviral vector-mediated gene transfer into repopulating hematopoietic cells.
Strom TS; Turner SJ; Andreansky S; Liu H; Doherty PC; Srivastava DK; Cunningham JM; Nienhuis AW
Blood; 2003 Nov; 102(9):3108-16. PubMed ID: 12855574
[TBL] [Abstract][Full Text] [Related]
20. Lentiviral vectors transcriptionally targeted to hematopoietic cells by WASP gene proximal promoter sequences.
Martín F; Toscano MG; Blundell M; Frecha C; Srivastava GK; Santamaría M; Thrasher AJ; Molina IJ
Gene Ther; 2005 Apr; 12(8):715-23. PubMed ID: 15750617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
